Dissocial behaviour in ecstasy users;Dissozialität bei ecstasykonsumenten

Sucht

Volumn 49, Issue 5, 2003, Pages 280-291

  Van Niekerk, Corinna ^b   Höfler, Michael ^b   Pfister, Hildegard ^b   Schütz, Christian ^b   Wittchen, Hans Ulrich ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b NONE

Author keywords

Amphetamines; Antisocial personality disorder; Conduct disorder; Ecstasy; Stimulants; Substance abuse

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CENTRAL STIMULANT AGENT; ILLICIT DRUG;

ADOLESCENT; ADULT; ANTISOCIAL BEHAVIOR; ARTICLE; DRUG ABUSE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARENTAL BEHAVIOR; PERSONALITY DISORDER; PREVALENCE; PSYCHOPATHY; SAMPLING; SOCIAL BEHAVIOR;

EID: 0242571797     PISSN: 09395911     EISSN: None     Source Type: Journal    
DOI: 10.1024/suc.2003.49.5.280     Document Type: Article

References (39)

1. American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington DC, APA.
2. Ball, S. A., Cecero, J. J. (2001). Addicted patients with personality disorders: Traits, schemas, and presenting problems. Journal of Personality Disorders, 15 (1), 72-83.
3. Booth, R. E., Zhang, Y. (1997). Conduct disorder and HIV risk behaviors among runaway and homeless adolescents. Drug and Alcohol Dependence, 48, 69-76.
4. Booth, B. M., Kirchner, J. E. (2001). Correlates and 6-month outcomes for co-occuring cannabis use in rural and urban at-risk drinkers. Substance Use and Misuse, 36 (6-7), 717-733.
5. Darke, S., Hall, W., Swift, W. (1994). Prevalence, symptoms and correlates of antisocial personality disorder among methadone maintenance clients. Drug and Alcohol Dependence, 34, 253-57.
6. Fydrich T., Renneberg, B., Schmitz B., Wittchen, H.-U. (1997). SKID II: Strukturiertes Klinisches Interview für DSM-IV (SKID-II), Achse II: Persönlichkeitsstörungen. Eine deutschsprachige, erweiterte Bearbeitung der amerikanischen Orginalversion des SCID-II von First, M. B., Spitzer, R. L., Gibbon, M., Williams, J. B. W., Benjamin, L. (Version 3/96). Göttingen, Hogrefe.
7. Gerra, G., Zaimovic, A., Ferri, M., Zimbelli, U., Timpano, M., Neri, E., Franco, G. F., Del signore, R., Brambilla, F. (2000). Long-Lasting Effects of (+/-)3,4-Methylenedioxymethamphetamine (Ecstasy) on Serotonin System Function in Humans. Society of Biological Psychiatry, 47, 127-136.
8. Gerra, G., Zaimovic, A., Ampollini, R., Giusti, F., Del signore, R., Raggi, M. A., La viola, G., Macchia, T., Brambilla, F. (2001). Experimentally induced aggressive behavior in subjects with 3,4-methylenedioxy-methamphetamine (»Ecstasy«) use history Psychobiological correlates. Journal of Substance Abuse, 13, 471-491.
9. Greenbaum, P. E., Prange, M. E., Friedman R. M., Silver S. E. (1991). Substance-abuse prevalence and comorbidity with other psychiatric-disorders among adolescents with severe emotional disturbances. Journal of the American Academy of Child and Adolescent Psychiatry, 30 (4), 575-583.
10. Höfler, M., Lieb, R., Perkonigg, A., Schuster, P., Sonntag, H., Wittchen, H.-U. (1999). Covariates of cannabis use progression in a representative population sample of adolescents: a prospective examination of vulnerability and risk factors. Addiction, 94 (11), 1679-1694.
11. Keller, M. B., Lavori, P. W., Beardslee, W., Wunder, J., Drs, D. L., Hasin, D. (1992). Clinical Course and Outcome of Substance Abuse Disorders in Adolescents. Journal of Substance Abuse Treatment, 9, 9-14.
12. Kovar, K.-A. (1998). Ecstasy: Status Quo des pharmakologisch/medizinischen Forschungsstandes. Forschung und Praxis der Gesundheitsförderung, Band 5. Bundeszentrale für gesundheitliche Aufklärung, Köln.
13. Lieb, R., Isensee, B., Sydow von, K., Wittchen, H.-U. (2000). The Early Developmental Stages of Psychopathology Study (EDSP): A Methodological Update. European Addiction Research, 6, 170-182.
14. Lieb, R., Schütz, C. G., Pfister, H., Sydow von, K., Wittchen, H.-U. (2002). Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug and Alcohol Dependence, 68, 195-207.
15. McCann, U., Ridenour, A., Shaham, Y., Ricaurte, G. A. (1994). Serotonin Neurotoxicity after (+/-)3,4-Methylenedioxymethamphetamine (MDMA; »Ecstasy«): A Controlled Study in Humans. Neuropsychopharmacology, 10, No. 2.
16. McCann, U., Szabo, Z., Scheffel, U., Dannals, R. F., Ricaurte, G. A. (1998). Positron emission tomographic evidence of toxic effect of MDMA (»Ecstasy«) on brain serotonin neurons in human beings. The Lancet, 352, October 31.
17. Miller, P., Plant, M. (2002). Heavy cannabis use among UK teenagers: an exploration. Drug and Alcohol Dependence, 65, 235-242.
18. Morgan, M.J. (1998). Recreational Use of »Ecstasy« (MDMA) Is Associated with Elevated Impulsivity. Neuropsychopharmacology, 19, No. 4.
19. Parrott, A. C. (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology: Clinical and Experimental, 16, 557-577.
20. Pedersen, W. & Skrondal, A. (1999). Ecstasy and new patterns of drug use: a normal population study. Addiction. 94 (11), 1695-1706.
21. Poethko-Müller, C. (1999). Neue pharmakologische und epidemiologische Erkenntnisse und deren praktische Bedeutung. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 42, 187-195.
22. Reed, V., Gander, F., Pfister, H., Steiger, A., Sonntag, H., Trenkwalder, C., Sonntag, A., Hundt, W., Wittchen, H.-U. (1998). To what degree does the Composite International Diagnostic Interview (CIDI) correctly identify DSM-IV disorders? Testing validity issues in a clinical sample. International Journal of Methods in Psychiatric Research, 7, 142-155.
23. Ricaurte, G. A., Byron, G., Strauss, L., Seiden, L., Schuster, C. (1985). Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229, 986-988.
24. Ricaurte, G. A., Forno, L. S., Wilson, L. E., DeLanney, L. E., Irwin, I., Molliver, M. E., Langston, J. W. (1988). (+/-)3,4-Metylenedioxymethamphetamine (MDMA) on central serotonergic neurons in non-human primates: neurochemical observations. Journal of Pharmacology and Experimental Therapeutics, 261 (2), 616-622.
25. Ricaurte, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J., McCann, U.D. (2002). Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA (»Ecst6asy«). Science, 297, 2260-2263.
26. Schifano, F., Di Furia, L., Forza, G., Minicuci, N., Bricolo, R. (1998). MDMA (»ecstasy«) consumption in the context of polydrug abuse: a report on 150 patients. Drug and Alcohol Dependence, 52, 85-90.
27. Schubiner, H., Tzelepis, A., Milberger, S., Lockhart, N., Kruger, M., Kelley, B. J., Schoener, E. P. (2000). Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. Journal of Clinical Psychiatry, 61 (4), 244-51.
28. Schuster, P., Wittchen, H.-U. (1996). Ecstasy- und Halluzinogengebrauch bei Jugendlichen - Gibt es eine Zunahme? Verhaltenstherapie, 6, 222-232.
29. Schuster, P., Lieb, R., Lamertz, C., Wittchen, H.-U. (1998). Is the Use of Ecstasy and Hallucinogens Increasing? Results from a Community Study. European Addiction Research, 4, 75-82.
30. StataCorp. (2001). Stata Statistical Software: Release 7.0. College Station, TX: Stata Corporation.
31. Stronski, S. M., Ireland, M., Michaud, P.-A., Narring, F., Resnick, M. D. (2000). Protective Correlates of Stages in Adolescent Substance Use: A Swiss National Study. Journal of Adolescent Health, 26, 420-427.
32. Sydow von, K., Lieb, R., Pfister, H., Höfler, M., Wittchen, H.-U. (2002). Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults - a transient phenomenon? Results from a longitudinal community study. Drug and Alcohol Dependence, 66, 147-159.
33. Thomasius, R., Schmolke, M., Kraus, D. (1997). MDMA (» Ecstasy«)-Konsum - ein Überblick zu psychiatrischen und medizinischen folgen. Fortschritte der Neurologie/Psychiatrie, 65, 49-61.
34. Tuchtenhagen, F., Daumann, J., Norra, C., Gebbelé, R., Becker, S., Pelz, S., Sass, H., Buchner, H., Gouzoulis-Mayfrank, E. (2000). High Intensity Dependence of Auditory Evoked Dipole Source Activity Indicates Decreased Serotonergic Activity in Abstinent Ecstasy (MDMA) Users. Neuropsychopharmacology, 22, 6.
35. Wittchen, H.-U., Pfister, H. (Eds.). (1997). DIA-X-Interviews: Manual für Screening-Verfahren und Interview: PC-Programm zur Durchführung des Interviews (Längs- und Querschnittsuntersuchung); Auswertungsprogramm. Frankfurt, Swets & Zeitlinger.
36. Wittchen H.-U., Lachner, G., Wunderlich, U., Pfister, H. (1998). Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Social Psychiatry and Psychiatric Epidemiology, 33, 568-578.
37. Wittchen, H.-U., Perkonigg, A., Lachner, G., Nelson, C. B. (1998a). Early develop mental stages of psychopathology study (EDSP): Objectives and design. European Addiction Research, 4, 18-27.
38. World Health Organisation. (1990). Composite International Diagnostic Interview (CIDI). Geneva, World Health Organisation.
39. World Health Organisation. (1993). Tenth revision of the international classification of diseases. ICD-10. Chapter V (F): Mental and behavioural disorders. Geneva, World Health Organisation.